|drug1059||Convalescent anti-SARS-CoV-2 plasma Wiki||1.00|
|drug2494||Nafamostat Mesilate Wiki||0.58|
|D011024||Pneumonia, Viral NIH||0.11|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled trial, which aims to assess the safety and efficacy of treatment with convalescent plasma for patients with moderate-severe COVID-19. Participants will be randomized 2:1 to two parallel treatment arms: Convalescent plasma, and intravenous placebo. Primary outcome is a composite endpoint of all-cause mortality or need of invasive mechanical ventilation up to 28 days.
Description: Composite outcomeMeasure: All-cause mortality or need of invasive mechanical ventilation Time: 28 days
Description: Number of participants with adverse events with possible relation to study drugMeasure: Frequency of adverse events Time: 90 days
Description: Number of participants with serious adverse events according to International Council of Harmonisation-Good Clinical Practice (ICH-GCP) guidelinesMeasure: Frequency of severe adverse events Time: 90 days
Description: Number of days to improvement of at least 2 categories relative to baseline on the ordinal scale. Categories are as follows: Death; Hospitalized, in intensive care requiring Extracorporeal Membrane Oxygenation (ECMO) or mechanical ventilation; Hospitalized, on non-invasive ventilation or high-flow oxygen device; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activitiesMeasure: Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status Time: 90 days
Description: Number of days without mechanical ventilationMeasure: Ventilator-free days Time: 28 days
Description: Number of days without organ-failureMeasure: Organ failure-free days Time: 28 days
Description: Number of days in ICUMeasure: Duration of ICU stay Time: 90 days
Description: Number of deaths by any causeMeasure: Mortality rate Time: 7, 14, 21, 28 and 90 days
Description: Days from the date of hospital admission for COVID-19 to the date of dischargeMeasure: Length of hospital stay Time: 90 days
Description: Days requiring supplement oxygenMeasure: Duration of supplemental oxygen Time: 90 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports